Kidswell Bio Corporation
4584.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥1,555,585 | ¥1,720,632 | ¥2,045,749 | ¥1,286,393 |
| % Growth | -9.6% | -15.9% | 59% | – |
| Cost of Goods Sold | ¥1,160,059 | ¥1,123,406 | ¥1,436,249 | ¥748,103 |
| Gross Profit | ¥395,526 | ¥597,226 | ¥609,500 | ¥538,290 |
| % Margin | 25.4% | 34.7% | 29.8% | 41.8% |
| R&D Expenses | ¥176,277 | ¥212,084 | ¥226,273 | ¥200,697 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥188,564 | ¥200,489 | ¥217,440 | ¥212,976 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥364,841 | ¥412,573 | ¥443,713 | ¥413,673 |
| Operating Income | ¥30,685 | ¥184,653 | ¥165,787 | ¥124,617 |
| % Margin | 2% | 10.7% | 8.1% | 9.7% |
| Other Income/Exp. Net | -¥119,026 | -¥9,036 | ¥41,177 | -¥17,820 |
| Pre-Tax Income | -¥88,341 | ¥175,617 | ¥206,964 | ¥106,797 |
| Tax Expense | ¥8,202 | ¥18,490 | ¥40,332 | ¥52,776 |
| Net Income | -¥96,543 | ¥157,126 | ¥166,633 | ¥54,021 |
| % Margin | -6.2% | 9.1% | 8.1% | 4.2% |
| EPS | -1.95 | 3.31 | 3.96 | 1.33 |
| % Growth | -158.9% | -16.4% | 197.7% | – |
| EPS Diluted | -1.95 | 3.28 | 3.96 | 1.33 |
| Weighted Avg Shares Out | 49,567 | 47,453 | 41,924 | 40,671 |
| Weighted Avg Shares Out Dil | 49,567 | 41,924 | 41,924 | 40,671 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥0 | ¥0 | ¥645 | ¥0 |
| Interest Expense | ¥8,235 | ¥9,552 | ¥10,111 | ¥9,672 |
| Depreciation & Amortization | ¥63 | ¥61 | ¥450 | -¥125,000 |
| EBITDA | -¥80,042 | ¥185,230 | ¥151,196 | ¥116,470 |
| % Margin | -5.1% | 10.8% | 7.4% | 9.1% |